Skip to main content

Table 3 Most Frequently Reported Adverse Events in Study 2 (Safety Population*)

From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

 

No. (%) of Subjects

Event

Placebo

(n = 4)

MEDI-528 50 mg

(n = 7)

Blood glucose increased

0 (0.0)

2 (28.6)

Back pain

1 (25.0)

1 (14.3)

Injection site irritation

1 (25.0)

1 (14.3)

Blood bicarbonate increased

0 (0.0)

1 (14.3)

Cyst

0 (0.0)

1 (14.3)

Lipase increased

0 (0.0)

1 (14.3)

Lower respiratory tract infection

0 (0.0)

1 (14.3)

Nuclear MRI abnormal

0 (0.0)

1 (14.3)

  1. Values are shown in descending order of frequency in the MEDI-528 group. MRI = magnetic resonance imaging.
  2. *Consisted of all subjects who received the study drug.